Teva Stock Soars on Early Bowel Disease Drug Data

Published on 17 Dec 2024 on Barrons.com

Teva and its partner Sanofi say 47.8% of patients with ulcerative colitis who received a high dose of their drug duvakitug experienced clinical...

Read the rest of the article

Start tracking your investments with Statfolio

Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than avera...

Zacks · via Yahoo Finance 18 Dec 2024

Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced...

Invezz 18 Dec 2024

Teva and Sanofi reported successful results in their phase 2 study of an IBD treatment. Both stoc...

Investing.com 18 Dec 2024

Teva stock soared 26.4% to 20.88 after briefly hitting its highest point since December 2018. San...

Investor's Business Daily 17 Dec 2024

Teva and Sanofi said they plan to launch a Phase 3 trial for duvakitug pending regulatory...

Investopedia · via Yahoo Finance 17 Dec 2024

Conducted across the U.S., Europe, and Israel, the trial met its primary endpoints, showing 47.8%...

GuruFocus.com · via Yahoo Finance 17 Dec 2024

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b...

Benzinga · via Yahoo Finance 17 Dec 2024

Teva and its partner Sanofi say 47.8% of patients with ulcerative colitis who received a high dos...

Barrons.com 17 Dec 2024

It also anticipates a portion of the costs of both these years to be reimbursed by Sanofi. How Ha...

Zacks · via Yahoo Finance 12 Dec 2024

Comings and goings at local biotech companies continue into the final days of the year, and the...

The Business Journals 12 Dec 2024